The Patent Finder

Syntaxin Limited

9 patents currently held · Updated Nov 18, 2026
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
9
Ending by 2030
Dec 2026
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 22, 2027
    The maintenance fee for Non-cytotoxic protein conjugates (US 9,139,635) comes due Mar 22, 2027. Unpaid by Sep 22, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

PatentTitleStatus Expires Confidence
US 7,659,092Fusion proteins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,124,405Fusion proteins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,072,736Treatment of pain
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,067,200Fusion Proteins
In force
 · Medium confidence
In forceMedium confidence
US 8,124,074Fusion proteins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,187,834Non-cytotoxic protein conjugates
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,139,635Non-cytotoxic protein conjugates
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,614,069Non-cytotoxic fusion proteins comprising EGF muteins
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,796,216Suppression of neuroendocrine diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 9: 14 patents in force now held by others · 17 lapsed for an unpaid fee · 30 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 abandoned · 9 no status recorded

Showing 1 to 10 of 13, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
14/459,955Aug 14, 2014No status recorded
14/250,959Apr 11, 2014No status recorded
14/422,574Fusion Proteins and Methods for Treating, Preventing or Ameliorating PainAug 27, 2013Abandoned
13/595,927Fusion ProteinsAug 27, 2012Abandoned
13/528,762Jun 20, 2012No status recorded
13/363,544Feb 1, 2012No status recorded
13/022,184Feb 7, 2011No status recorded
12/969,826Dec 16, 2010No status recorded
12/868,510Fusion ProteinsAug 25, 2010Abandoned
13/125,407Nov 17, 2009No status recorded
10 of 13 applications shown.
Pro members see all 13 published applications.
Pro members: see all 13 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited